Drug Trial Radar · NCT02847429
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Last checked: Nov 19, 2026Latest source record: Jan 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 2016
Primary completion
Aug 2021
Study completion Aug 2021
Sponsor
- Lead sponsor
- Arog Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Centre Leon Berard; Fox Chase Cancer Center
- First posted
- Jul 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximately 120 subjects will be randomized in a 2:1 ratio to receive either crenolanib 100 mg or matching placebo orally (PO) 3 times daily (TID) in combination with best supportive care.
Conditions
- GIST With D842V Mutated PDGFRA Gene
Interventions
CrenolanibDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) will be measured from the date of randomization to the date of the first objective radiological disease progression according to centralized committee assessment using modified RECIST version 1.1 or death.Time frame: 3 years
Locations
23 sites in 7 countries. Site status is shown where the registry gives one.
Sarcoma Oncology Center
Santa Monica, California
University of Miami
Miami, Florida
Duke Cancer Institute
Durham, North Carolina
Oregon Health and Science University
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
La Timone University Hospital
Marseille, France
Centre Hospitalier Universitaire (CHU) de Reims
Reims, France
HELIOS Klinikum Berlin-Buch
Berlin, Germany
Mannheim University Medical Centre, University of Heidelberg
Mannheim, Germany
Universitätsklinikum München
Munich, Germany
Policlinico S. Orsola-Malpighi
Bologna, Italy
Istituto Nazionale Tumori
Milan, Italy
Institut Regina Elena / IFO
Rome, Italy
Candiolo Cancer Institute - FPO, IRCCS
Turin, Italy
University Hospital The Norwegian Radium Hospital
Oslo, Norway
M Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology
Warsaw, Poland
Vall d'Hebron University Hospital
Barcelona, Spain
Hospital Universitario Puerta de Hierro
Madrid, Spain
Hospital Virgen del Rocio
Seville, Spain
Fundación Instituto Valenciano de Oncología
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.